Evidence map›Paper›PMID 25909172›Full record

ArticleOncotarget2015

Selective killing of breast cancer cells expressing activated CD44 using CD44 ligand-coated nanoparticles in vitro and in vivo.

Cuixia Yang, Yiqing He, Huizhen Zhang, Yiwen Liu, Wenjuan Wang, Yan Du, Feng Gao

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 53 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Cuixia YangDepartment of Molecular Biology Laboratory, Shanghai Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, China.
Yiqing HeDepartment of Molecular Biology Laboratory, Shanghai Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, China.
Huizhen ZhangDepartment of Pathology, Shanghai Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, China.
Yiwen LiuDepartment of Molecular Biology Laboratory, Shanghai Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, China.
Wenjuan WangDepartment of Clinical Laboratory, Shanghai Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, China.
Yan DuDepartment of Molecular Biology Laboratory, Shanghai Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, China.
Feng GaoDepartment of Molecular Biology Laboratory, Shanghai Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, China.
Shanghai Sixth People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The cell surface glycoprotein CD44 is expressed in cancer cells and has been used as a therapeutic target in preclinical studies. However, the ubiquitous expression of CD44 in numerous cell types, including hematopoietic cells, has hindered its application in targeted therapy. Here, we demonstrated that CD44 was activated on breast cancer cells but was inactive on normal cells in vitro and in vivo. We analyzed 34 clinical primary tumor and normal breast tissues and demonstrated that CD44 was in an active state on breast cancer cells but in an inactive state on normal cells. Furthermore, based on the binding property of CD44 with its ligand hyaluronan (HA), we self-assembled HA-coated nanoparticles and studied their selective targeting efficacy. Our results indicate that HA-coated nanoparticles bearing the CD44 ligand selectively targeted cancer cells both in vitro and in vivo, killing breast cancer cells while sparing normal cells. Our study suggested that the active state of CD44 plays a crucial role in the selective targeting of breast cancer cells by avoiding nonspecific toxicity to CD44-quiescent normal cells. These findings may provide a new idea for the selective targeting of cancer cells in other human cancers.

Indexed as

3T3 CellsAnimalsAntineoplastic Agents, PhytogenicBreast NeoplasmsCell Line, TumorCell MovementCell ProliferationChlorocebus aethiopsDrug CarriersFemaleHumansHyaluronan ReceptorsHyaluronic AcidMiceNanoparticlesPaclitaxelAntineoplastic Agents, PhytogenicCD44 protein, humanDrug CarriersHyaluronan ReceptorsHyaluronic AcidPaclitaxelbreast cancerCD44hyaluronanselective targeting therapy

Identifiers

PMID25909172
PMCPMC4558151
OpenAlexW1580509806

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.